All manuscripts
Publications CAR T Cells

Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies

Published Journal Molecular Therapy

Share
No image preview

Overview

The study demonstrates manufacturing of CD7 CAR T cells using ibrutinib/dasatinib to prevent fratricide. cGMP manufacturing involved transduction and expansion in G-Rex® culture devices for 3 additional days.

What this paper found

Supplementing cultures with the kinase inhibitors ibrutinib (200 nM) and dasatinib (200 nM) prevented fratricide of CD7 CAR T cells made from unedited peripheral blood T cells, so that CD7 gene knockout was unnecessary. Treated cells kept high CAR expression, remained viable and expanded normally, and regained cytotoxicity against Jurkat and CCRF-CEM T-ALL lines once the inhibitors were withdrawn. In NSG mice engrafted with either leukemia, these cells persisted long term, controlled disease and prolonged survival, outgrowing as a CD7-negative population transcriptionally very similar to CD7-edited CAR T cells. Three autologous products manufactured under cGMP from patients with T-ALL expanded a mean 78.8-fold over 4 days, with 94.7% viability, 95.3% CAR expression and 90.0% cytotoxicity.

Note: The authors note that once the inhibitors are removed CAR signaling resumes and brings back fratricide, which limited expansion of these cells in tumor coculture assays and delayed their initial expansion in vivo.

Taken together, these results support efficacy and feasibility of manufacturing unedited CD7 CAR T cells with potent anti-tumor activity by using pharmacologic inhibition of CAR-mediated fratricide in lieu of genome editing or incorporating additional transgenes. — Norihiro Watanabe, Feiyan Mo, Rong Zheng, Royce Ma, Vanesa C. Bray, Dayenne G. van Leeuwen, Juntima Sritabal-Ramirez, Hongxiang Hu, Sha Wang, Birju Mehta, Madhuwanti Srinivasan, Lauren D. Scherer, Huimin Zhang, Sachin G. Thakkar, LaQuisa C. Hill, Helen E. Heslop, Chonghui Cheng, Malcolm K. Brenner, Maksim Mamonkin, Molecular Therapy

Study details

Authors
Norihiro Watanabe, Feiyan Mo, Rong Zheng, Royce Ma, Vanesa C. Bray, Dayenne G. van Leeuwen, Juntima Sritabal-Ramirez, Hongxiang Hu, Sha Wang, Birju Mehta, Madhuwanti Srinivasan, Lauren D. Scherer, Huimin Zhang, Sachin G. Thakkar, LaQuisa C. Hill, Helen E. Heslop, Chonghui Cheng, Malcolm K. Brenner, Maksim Mamonkin
Institution
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, USA · Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA · Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA · Department of Molecular and Human Genetics, Lester & Sue Breast Center, Baylor College of Medicine, Houston, TX, USA · Graduate Program in Integrative Molecular and Biomedical Sciences, Baylor College of Medicine, Houston, TX, USA · Graduate Program in Immunology, Baylor College of Medicine, Houston, TX, USA · Graduate Program in Immunology and Microbiology, Baylor College of Medicine, Houston, TX, USA · Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA
Journal
Molecular Therapy
Year
2022
PMID / PMC
PMID: 36086817 · PMC
Cell type(s)
CAR T Cells
Application area
Hematologic malignancy
Study phase
Preclinical

How G-Rex® was used

In the cGMP manufacture of autologous unedited CD7 CAR T cells, patient PBMCs were stimulated with anti-CD3/anti-CD28 antibodies in T75 flasks with 200 nM ibrutinib and transduced three days later with a clinical-grade CD7 CAR gammaretroviral vector in retronectin-coated flasks. The cells were moved into G-Rex® culture devices the following day and expanded there for 3 more days in fresh medium supplemented with ibrutinib, dasatinib, IL-7 and IL-15. On day 4 after transduction the T cells were collected, counted and cryopreserved under FDA-approved cGMP SOPs, with a mean 78.8-fold expansion across the three patient products.

Explore related

Full citation

Watanabe N, Mo F, Zheng R, et al. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Mol Ther. 2023;31(1):24-34.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →